II. Background

  1. Planned release 2018 in U.S.

III. Mechanism

  1. Antidote for Eliquis (Apixaban) or Xarelto (Rivaroxaban), but not other Factor Xa Inhibitors
  2. Andexxa Binds Factor Xa Inhibitors

IV. Efficacy

  1. Limits progression of bleeding within 12 hours of dose (onset as early as 1 hour)

V. Adverse Effects

  1. Expensive: $25,000 to 50,000 per patient
  2. Risk of Hypercoagulability complications (CVA, VTE)

VI. References

  1. (2018) Presc Lett 25(7): 37-8

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window